Maoxing Biotech's universal CAR-T targeting B7-H3 has received FDA's Fast Track designation, facilitating the global development of intracranial solid tumors._新闻中心_T-MAXIMUM Biotech

Maoxing Biotech's universal CAR-T targeting B7-H3 has received FDA's Fast Track designation, facilitating the global development of intracranial solid tumors.

Author: Release time: 2026/8/31 10:18:22

Previous:T-MAXIMUM Pharmaceutical's Allogeneic CAR-T Therapy MT027 Receives FDA IND Clearance to Proceed to Phase II clinical Trial for Recurrent Glioblastoma

Next:Nothing